Orasis Pharmaceuticals announced the initiation of a phase 2b clinical study in the United States evaluating CSF-1 for the treatment of presbyopia. The phase 2b study is a multicenter, double-masked trial in the United States enrolling 150 participants with presbyopia to evaluate the efficacy and safety of CSF-1. The study started enrolling patients in February 2019. All study sites are actively recruiting participants aged 45 to 64 with presbyopia.
“We are excited to initiate the phase 2b clinical trial evaluating our corrective eye drop as it marks a key milestone in its clinical development,” Elad Kedar, chief executive officer of Orasis, said in a company news release. “CSF-1 has the potential to restore near vision and offer an alternative to current treatment options, which are either cumbersome or invasive. We look forward to sharing the results from this study in the near future as we advance the development of CSF-1 in the clinic for the treatment of presbyopia, a condition that affects more than 1.8 billion people worldwide.”